Assessing the current role of platelet function testing

Clinical Cardiology

Volumn 31, Issue 3 SUUPL. 1, 2008, Pages

  Braunwald, Eugene ^a   Angiolillo, Dominick ^b   Bates, Eric ^c   Berger, Peter B ^d   Bhatt, Deepak ^e   Cannon, Christopher P ^a   Furman, Mark I ^f   Gurbel, Paul ^g   Michelson, Alan D ^h   Peterson, Eric ⁱ   Wiviott, Stephen ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f South Shore Hospital   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; THROMBOXANE B2; VASODILATOR STIMULATED PHOSPHOPROTEIN;

BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONFERENCE PAPER; DRUG RESPONSE; HUMAN; IMPEDANCE AGGREGOMETRY; IN VITRO STUDY; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; TREATMENT OUTCOME; TURBIDOMETRIC PLATELET AGGREGOMETRY;

BLOOD PLATELETS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; EQUIPMENT DESIGN; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 41149124328     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20361     Document Type: Conference Paper

References (25)

1. Michelson AD: Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb 2006;35:67-82
2. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD: Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834
3. Michelson AD: Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-e493
4. Michelson AD, Frelinger AL III, Furman MI: Current options in platelet function testing. Am J Cardiol 2006;98:S4-S10
5. Harrison P, Keeling D: Clinical tests of platelet function. In: Michelson AD, ed. Platelets. 2nd ed. Elsevier, Inc./Academic Press; San Diego, CA: 2007; 445-474
6. Michelson AD, Frelinger AL III, Furman MI: Current options in platelet function testing. Am J Cardiol 2006;98(10A): 4N-10N
7. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, el al.: Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance. J Thromb Haemost 2007;5:75-81
8. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105: 1650-1655
9. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965
10. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235
11. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, et al.: Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006;4:1271-1278
12. Chen WH, Lee PY, Ng W, Tse HF, Lau CP, et al.: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126
13. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R. et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
14. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, et al.: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 2005;46:1827-1832
15. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P. et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Intern 2003;59:295-302
16. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W. et al.: Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 2005;45:1753-1756
17. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, et al.: Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-1752
18. Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology: Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004;25:166-181
19. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, et al. For the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis: Working Group on Aspirin Resistance: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-1311
20. American College of Cardiology/American Heart Association Task Force on Practice Guidelines: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation 2006;113:e1-e121
21. Gurbel PA: The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovasclar risk factor. Rev Cardiovasc Med 2007;7:S20-S28
22. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD: Platelet function moniroting in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834
23. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130
24. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, et al.: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521
25. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, et al.: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202